ODAC rejects Marqibo

FDA's Oncologic Drugs Advisory Committee voted unanimously against accelerated approval for Marqibo vincristine from Inex (TSE:IEX) and Enzon (ENZN) to treat

Read the full 215 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE